Founded in 2023 as a spin-out of Gustave Roussy, Orakl Oncology is a TechBio company using AI and real patient biology to predict how cancer drugs will perform in clinical trials.

AI can now predict protein structures and design new molecules. Yet one of drug development’s biggest challenges remains unresolved: predicting whether a promising treatment will actually work in patients. AI-designed cancer drugs still stumble in Phase 2, where around 75% of oncology candidates fail 1, largely because the complexity of patient and tumor biology remains poorly understood.

Orakl bridges biological and artificial intelligence by building cohorts of virtual cancer patients: real patients’ tumors, grown in the lab and paired with their medical history and deep biological data. Because these virtual patients can be tested against treatments at scale, Orakl can predict, with causal evidence, how a patient will respond to a drug many years before it reaches the clinic. Pharma companies can then bet on the right drugs, for the right patients, much earlier.

The company’s predictive engine has demonstrated 90% accuracy in predicting cancer clinical trial outcomes, including predictions that closely anticipated recent pancreatic cancer trial results. Beyond predicting clinical endpoints, the platform can identify which patients are most likely to respond to a treatment and uncover biological mechanisms of sensitivity and resistance. Candidate targets are then validated on Orakl’s proprietary patient-derived models through a lab-in-the-loop approach, building a pipeline of high-conviction targets while continuously improving its AI models, and opening new opportunities for therapeutic target discovery.

Through its international hospital network, Orakl is building a continuously expanding proprietary dataset combining patient biology, clinical information and experimental drug-response data. More than 15 additional cancer centers across Europe, North America and Asia are in contract negotiations, as Orakl aims to build the most comprehensive dataset in oncology.

Just over a year after its commercial launch, with 18 of the world’s top 20 pharmaceutical companies in its commercial pipeline, Orakl is already converting its first pharmaceutical engagements into multiyear collaborations.

In November 2026, InfraVia invested in Orakl Oncology as part of its $34 million funding round, co-led by Norrsken VC and Singular. The funding will support the Company’s next phase of growth, including the expansion of its proprietary dataset and AI capabilities, the extension of its platform to additional cancer types, the development of new pharmaceutical partnerships in the US and UK, and the expansion of its capabilities into therapeutic target discovery.